
BGB-8035
CAS No. 2283349-24-4
BGB-8035( —— )
Catalog No. M36520 CAS No. 2283349-24-4
BGB-8035 is an orally available, selective and potent BTK inhibitor with antitumor activity that inhibits BTK, TEC and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
2MG | 628 | Get Quote |
![]() ![]() |
5MG | 933 | Get Quote |
![]() ![]() |
10MG | 1254 | Get Quote |
![]() ![]() |
25MG | 1812 | Get Quote |
![]() ![]() |
50MG | 2374 | Get Quote |
![]() ![]() |
100MG | 3060 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameBGB-8035
-
NoteResearch use only, not for human use.
-
Brief DescriptionBGB-8035 is an orally available, selective and potent BTK inhibitor with antitumor activity that inhibits BTK, TEC and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.
-
DescriptionBGB-8035 is an orally active, highly selective bruton's tyrosine kinase (BTK) inhibitor with IC50s of 1.1 nM, 99 nM, 621 nM for BTK, TEC, EGFR, respectively. BGB-8035 has antitumor and anti-arthritis activity. BGB-8035 has the potential for B-cell malignancies and autoimmune diseases research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK | EGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2283349-24-4
-
Formula Weight453.53
-
Molecular FormulaC24H31N5O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(N)(=O)C1=C2N([C@@H](CCN2)C3CCN(C(C=C)=O)CC3)N=C1C4=CC(OC)=C(C)C(OC)=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Yunhang Guo, et al. Discovery of BGB-8035, a Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase for B-Cell Malignancies and Autoimmune Diseases. J Med Chem. 2023 Mar 23;66(6):4025-4044.?
molnova catalog



related products
-
NX-2127
NX-2127 (ETX2514 Triethylamine) is an orally active BTK inhibitor that induces degradation of mutant BTKC481S in cells.NX-2127 has potent antiproliferative activity and inhibits the proliferation of BTKC481S mutant TMD8 cells.
-
BTK inhibitor 4b
BTK inhibitor 4b is a potent, highly selective inhibitors of BTK with IC50 of 4.2 and 0.9 nM against activated and unactivated BTK, respectively.
-
Vecabrutinib
Vecabrutinib (SNS-062) is a potent, reversible, non-covalent BTK inhibitor with IC50 of 2.9 and 4.4 nM for WT BTK and C481S BTK, respectively;